- Home
- AVDX vs COGT Comparison
AVDX vs COGT Comparison
Compare AVDX & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- COGT
- Stock Information
- Founded
- AVDX 2000
- COGT 2014
- Country
- AVDX United States
- COGT United States
- Employees
- AVDX N/A
- COGT N/A
- Industry
- AVDX EDP Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- AVDX Technology
- COGT Health Care
- Exchange
- AVDX Nasdaq
- COGT Nasdaq
- Market Cap
- AVDX 2.1B
- COGT 2.3B
- IPO Year
- AVDX 2021
- COGT 2018
- Fundamental
- Price
- AVDX $10.01
- COGT $15.60
- Analyst Decision
- AVDX Hold
- COGT Strong Buy
- Analyst Count
- AVDX 14
- COGT 11
- Target Price
- AVDX $9.73
- COGT $21.20
- AVG Volume (30 Days)
- AVDX 2.0M
- COGT 2.0M
- Earning Date
- AVDX 11-05-2025
- COGT 11-11-2025
- Dividend Yield
- AVDX N/A
- COGT N/A
- EPS Growth
- AVDX N/A
- COGT N/A
- EPS
- AVDX N/A
- COGT N/A
- Revenue
- AVDX $446,722,000.00
- COGT N/A
- Revenue This Year
- AVDX $5.52
- COGT N/A
- Revenue Next Year
- AVDX $9.64
- COGT N/A
- P/E Ratio
- AVDX N/A
- COGT N/A
- Revenue Growth
- AVDX 8.04
- COGT N/A
- 52 Week Low
- AVDX $6.61
- COGT $3.72
- 52 Week High
- AVDX $11.68
- COGT $16.99
- Technical
- Relative Strength Index (RSI)
- AVDX 70.73
- COGT 63.69
- Support Level
- AVDX $9.89
- COGT $15.26
- Resistance Level
- AVDX $10.02
- COGT $16.99
- Average True Range (ATR)
- AVDX 0.02
- COGT 0.71
- MACD
- AVDX 0.00
- COGT 0.10
- Stochastic Oscillator
- AVDX 87.37
- COGT 63.72
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.